Vitamin Е activates expression of С/EBP alpha transcription factor and G-CSF receptor in leukemic K562 cells
Keywords:
C/EBP alpha transcription factor, chronic myeloid leukemia, G-CSFR, granulocytic differentiation, vitamin E.Abstract
Summary. Background: Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder associated with the activity of BCR-ABL fusion oncogene. Tyrosine kinase inhibitors are the current treatment of CML, but secondary mutations finally contribute to therapy resistance and blast crisis of the disease. The search for the novel compounds for the effective control of CML is now in the spotlight. The progression of CML to blast crisis is correlated with down-modulation of C/EBP alpha. Therefore, C/EBP alpha may be considered as a putative target in differentiation therapies in myeloid leukemias. The aim of the study was to assess the potential of vitamin E as the possible inducer of C/EBP alpha expression in BCR-ABL-positive CML K562 cells. Materials and Methods: RNA extracted from K562 cells cultured with valproic acid or vitamin E was converted to cDNA, RT-PCR reactions were carried out using HotStarTaq DNA polymerase with primers for C/EBP alpha and granulocyte colony-stimulating factor receptor (G-CSFR). Results: We have not found detectable expression of C/EBP alpha in K562 cells. Upon 48-h culture with vitamin E at a dose of 100 µM, K562 cells expressed both C/EBP alpha and G-CSFR. Conclusion: Vitamin E restored the expression of C/EBP alpha mRNA in chronic myelogenous leukemia K562 cells. In this setting, G-CSFR expression in vitamin E treated K562 cells seems to suggest the activation to granulocytic differentiation. It should be further elucidated whether such effects of vitamin E on C/EBP alpha transcription factor are direct or mediated indirectly due to antioxidant properties of vitamin E.
References
Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010–22.
Gluzman DF, Sklyarenko LM, Nadgornaya VA. Tumours of haematopoietic and lymphoid tissues (cytomorphology, immunocytochemistry, diagnostic algorithms). Kyiv: DIA, 2008. 193 p. (in Russian).
Sayyler V, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003; 40: 4–10.
Morotti A, Panuzzo C, Fava C, Saglio G. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia. Expert Opin Biol Ther 2014; 14: 287–99.
Soverini S, Mancini M, Bavaro L, et al. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer 2018; 17: 49.
Perrotti D, Neviari P. Resetting PP2a tumor suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukemia. Br J Cancer 2006; 95: 775–81.
Sangodkar J, Farrington CC, McClinch K, et al. All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase. FEBS J 2016; 283: 1004–24.
Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Сancer Cell 2005; 8: 355–68.
Voronkov M, Braitwaite SP, Stockt JB. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer’s disease. Future Med Chem 2011; 3: 821–33.
Perrotti D, Cesi V, Trotta R, et al. BCR/ABL suppresses C/EBR expression through inhibitory action of RNPE2. Nat Genet 2002; 30: 48–58.
Chang JS, Santhanam R, Trotta R, et al. High levels of BCR-ABL oncoprotein are required for the MAP-hnRNP-E2-dependent suppression of C/EBPα-driven myeloid differentiation. Blood 2007; 10: 994–1002.
Sasaki K, Yamagata T, Mitani K. Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera. Cancer Sci 2008; 99: 414–22.
Liu N, Wang C, Wang L, et al. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis. Int J Mol Med 2016; 37: 1686–96.
Porse BT, Bryder D, Theilgaard-Monch K, et al. Loss of C/EBP alpha cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage. J Exp Med 2005; 202: 85–96.
Avellino R, Delvel R. Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation. Blood 2017; 129: 2083–91.
Dong F, Zhang G, Zhang X, et al. Aberrantly expressed transcription factors C/EBP and SOX4 have positive effects in the development of chronic myeloid leukemia. Mol Med Rep 2017; 16: 7131–7.
Tavor S, Park DJ, Gery S, et al. Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. J Biol Chem 2003; 278: 52651–9.
Iacomino G, Medici MC, Russo GL. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Anticancer Res 2008; 28: 855–64.
Zapotocky M, Mejstrikova E, Smetana K, et al. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically. Cancer Lett 2012; 319: 144–53.
Wang Q.F., Friedman A.D. CCAAT/enhancer-binding proteins are required for granulopoiesis independent of their induction of the granulocyte colony-stimulating factor receptor. Blood 2002; 99: 2776–85.
Zhang P, Wang ND, Hetherington CJ, et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 1997; 94: 569–74.
Nakajima H, Ihle JN. Granulocyte colony-stimulating factor regulates myeloid differentiation through CCAAT/enhancer-binding protein epsilon. Blood 2001; 98: 897–905.
Paz-Priel I, Friedman AD. C/EBPα Dysregulation in AML and ALL. Crit Rev Oncog 2012; 16: 93–102.
Pullikan JA, Tenen DG, Behre G. C/EBPα deregulation as a paradigm for leukemogenesis. Leukemia 2017; 31: 2279–85.
Kagita S, Uppalapati S, Gungeti S, Digumarti R. Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukemia. Jpn J Clin Oncol 2015; 45: 749–54.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
